MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
LivaNova PLC Operating Income 2011-2026 | LIVN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income LivaNova PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 129 M | -68.5 M | -76.8 M | -784 K | -274 M | -172 M | -248 M | 96.5 M | 33.4 M | 88.7 M | 80 M | 78.3 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 129 M | -274 M | -27.8 M |
Quarterly Operating Income LivaNova PLC
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 M | 54.2 M | 48.6 M | - | 35.6 M | 40.2 M | 16.2 M | - | 4.46 M | 17.4 M | -2.34 M | - | -132 M | 31.8 M | 9.5 M | 24.8 M | 16.4 M | -36.3 M | -5.7 M | -249 M | -7.55 M | -16.7 M | -15.2 M | -144 M | 25.8 M | -29.9 M | -20.8 M | -276 M | -5.76 M | 21.6 M | 12.5 M | 18.9 M | 30 M | 27.8 M | 19.7 M | -14.9 M | 30.4 M | 25 M | -9.07 M | - | -26.4 M | -26.4 M | 16.7 M | - | 26.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.2 M | -276 M | -10.3 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 21.04 | 0.86 % | $ 3.01 B | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.5 | 1.74 % | $ 121 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.4 | 1.08 % | $ 675 M |  Israel |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 95.35 | -0.69 % | $ 140 B | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 302.99 | -0.5 % | $ 8.55 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 29.12 | 1.01 % | $ 246 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 47.11 | -0.84 % | $ 7.02 K | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 125.29 | -0.39 % | $ 218 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.29 | 2.49 % | $ 123 M |  France |
 |
InMode Ltd.
INMD
|
113 M | $ 14.69 | -1.01 % | $ 1.17 B | Israel |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 97.28 | -0.5 % | $ 1.23 B | USA |
|
LENSAR
LNSR
|
-10.7 M | $ 11.63 | - | $ 134 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Myomo
MYO
|
-10.7 M | $ 0.91 | -1.58 % | $ 6.42 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Zynex
ZYXI
|
5.99 M | - | - | $ 21.1 M | USA |
 |
Orthofix Medical
OFIX
|
-84.6 M | $ 15.16 | -1.11 % | $ 578 M |  Curacao |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 156.15 | -1.26 % | $ 11.7 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.82 | 2.64 % | $ 84.3 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 13.68 | 0.81 % | $ 370 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.56 | -0.22 % | $ 122 M | USA |
 |
AxoGen
AXGN
|
-3.29 M | $ 32.73 | - | $ 1.45 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
-13.4 M | $ 3.86 | 2.66 % | $ 14.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.14 | -0.87 % | $ 18.4 M | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 40.6 | -1.31 % | $ 1.25 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-35 M | $ 17.76 | -1.11 % | $ 410 M | USA |